BR112018074275A2 - anticorpo de penetração no citosol e método de produção do mesmo - Google Patents

anticorpo de penetração no citosol e método de produção do mesmo

Info

Publication number
BR112018074275A2
BR112018074275A2 BR112018074275A BR112018074275A BR112018074275A2 BR 112018074275 A2 BR112018074275 A2 BR 112018074275A2 BR 112018074275 A BR112018074275 A BR 112018074275A BR 112018074275 A BR112018074275 A BR 112018074275A BR 112018074275 A2 BR112018074275 A2 BR 112018074275A2
Authority
BR
Brazil
Prior art keywords
cytosol
antibody
penetration antibody
production method
identification
Prior art date
Application number
BR112018074275A
Other languages
English (en)
Inventor
Yeong Park Jae
Sun Kim Ji
Sung Kim Yong
Original Assignee
Orum Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020160065365A external-priority patent/KR102000000B1/ko
Priority claimed from KR1020160065379A external-priority patent/KR20170133933A/ko
Application filed by Orum Therapeutics Inc filed Critical Orum Therapeutics Inc
Priority claimed from KR1020170065670A external-priority patent/KR20180129514A/ko
Publication of BR112018074275A2 publication Critical patent/BR112018074275A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

anticorpo de penetração no citosol e método de produção do mesmo refere-se a presente invenção a um anticorpo de penetração no citosol e sua utilização e, mais especificamente a identificação de um mecanismo estrutural que induz um escape a partir de endossomas no citosol depois da internalização celular em células vivas através da proteína de membrana celular, uma região variável de cadeia leve e/ou região variável de cadeia pesada que é baseada nesta identificação e tem uma capacidade significativamente melhorada de escapar de endossomas no citosol, um anticorpo de penetração no citosol compreendendo o mesmo, um método para produzir o mesmo e a utilização do mesmo.
BR112018074275A 2016-05-27 2017-05-26 anticorpo de penetração no citosol e método de produção do mesmo BR112018074275A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR1020160065365A KR102000000B1 (ko) 2016-05-27 2016-05-27 항체에 엔도좀 탈출능을 부여하는 엔도좀 탈출 구조 모티프 및 이의 활용
KR1020160065379A KR20170133933A (ko) 2016-05-27 2016-05-27 항체의 상보성 결정 영역의 구조적 변화를 유도하기 위한 방법
PCT/KR2017/005559 WO2017204606A1 (ko) 2016-05-27 2017-05-26 세포질 침투 항체 및 이의 용도
KR1020170065670A KR20180129514A (ko) 2017-05-26 2017-05-26 세포질 침투 항체 및 이의 용도

Publications (1)

Publication Number Publication Date
BR112018074275A2 true BR112018074275A2 (pt) 2019-10-01

Family

ID=60412784

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018074275A BR112018074275A2 (pt) 2016-05-27 2017-05-26 anticorpo de penetração no citosol e método de produção do mesmo

Country Status (8)

Country Link
US (1) US11155641B2 (pt)
JP (1) JP2019520086A (pt)
AU (1) AU2017271189B2 (pt)
BR (1) BR112018074275A2 (pt)
CA (1) CA3025757A1 (pt)
IL (1) IL263242A (pt)
MX (1) MX2018014554A (pt)
WO (1) WO2017204606A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101602876B1 (ko) 2014-07-22 2016-03-11 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용
KR101602870B1 (ko) 2014-07-22 2016-03-21 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
JP7165943B2 (ja) * 2017-11-01 2022-11-07 東洋紡株式会社 π電子共役単位とカルバゾール基を有する化合物
WO2019132579A2 (ko) * 2017-12-28 2019-07-04 오름테라퓨틱 주식회사 세포질 침투 항체에 융합된 rna 분해효소를 포함하는 면역독소
WO2019244086A1 (en) * 2018-06-21 2019-12-26 Orum Therapeutics Inc. Cell/tissue-specific cell-penetrating antibodies
CN116648262A (zh) * 2020-12-23 2023-08-25 中外制药株式会社 具有改善的胞质溶胶穿透活性的抗原结合分子
WO2023003339A1 (ko) 2021-07-20 2023-01-26 아주대학교산학협력단 세포 내부에 침투하여 표적단백질을 분해하여 제거하는 세포침투 분해항체 및 이의 용도

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
EP0349578B2 (en) 1987-03-02 1998-10-28 Enzon Labs Inc. Organism carrying a Single Chain Antibody Domain at its surface.
AU605291B2 (en) 1987-03-20 1991-01-10 Micromet Ag Process for the purification of recombinant polypeptides
AU601273B2 (en) 1987-03-20 1990-09-06 Creative Biomolecules, Inc. Leader sequences for the production of recombinant proteins
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
FR2706486B1 (fr) 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
CN1241574A (zh) 1998-07-02 2000-01-19 中国人民解放军第四军医大学 抗肝癌单克隆抗体HAb25及其单链抗体和双功能抗体
GB0226727D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intrabodies
WO2003077945A1 (en) 2002-03-14 2003-09-25 Medical Research Council Intracellular antibodies
JP2006521088A (ja) 2002-11-15 2006-09-21 メディカル リサーチ カウンシル 抗活性化ｒａｓ抗体
MX2008012392A (es) 2006-03-27 2008-12-17 Globeimmune Inc Mutacion de ras, y composiciones y metodos relacionados con la misma.
CA2711256C (en) 2008-01-03 2019-01-15 The Scripps Research Institute Antibody targeting through a modular recognition domain
KR100849941B1 (ko) 2008-04-29 2008-08-01 원우이에프엔지니어링주식회사 열 및 연기 화재감지장치 복합시험기
WO2009134027A2 (en) 2008-04-30 2009-11-05 Ajou University Industry-Academic Cooperation Foundation Anti-nucleic acid antibody inducing cell death of cancer cells and composition for preventing or treating cancers comprising the same
KR101075123B1 (ko) 2008-10-24 2011-10-19 아주대학교산학협력단 핵산가수분해 능 및 암세포내 침투능력을 갖는 인간화된 항체 및 그 용도
CN102209726A (zh) 2008-11-11 2011-10-05 亚州大学校产学协力团 具有细胞穿透性、序列特异性和核酸水解性的抗体、其制备方法及包含所述抗体的药物组合物
CN101402675B (zh) 2008-11-28 2012-05-30 中国人民解放军第三军医大学第三附属医院 一种靶向抑制ανβ3阳性细胞增殖的环肽
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
GB201103631D0 (en) 2011-03-03 2011-04-13 Univ Leeds Identification of candidate therapeutics
JP6178785B2 (ja) 2011-04-01 2017-08-09 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 細胞浸透性抗ｄｎａ抗体およびｄｎａ修復を阻害するためのその使用
US9283272B2 (en) 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
WO2014042209A1 (ja) 2012-09-14 2014-03-20 公益財団法人がん研究会 ＥｐＣＡＭに結合するペプチド
WO2015048477A1 (en) 2013-09-27 2015-04-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Cyclic peptide conjugates and methods of use
WO2016013870A1 (ko) 2014-07-22 2016-01-28 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
WO2016013871A1 (ko) 2014-07-22 2016-01-28 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용
KR101602876B1 (ko) * 2014-07-22 2016-03-11 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용
KR101602870B1 (ko) 2014-07-22 2016-03-21 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
KR20170132793A (ko) 2015-04-03 2017-12-04 유레카 쎄라퓨틱스, 인코포레이티드 Afp 펩티드/mhc 복합체를 표적화하는 구축물 및 그의 용도
KR101790669B1 (ko) 2015-10-14 2017-10-26 아주대학교산학협력단 개선된 분할 녹색 형광 단백질 상보 시스템 및 이의 용도
KR101836392B1 (ko) 2016-08-17 2018-03-08 한림대학교 산학협력단 사이클릭 펩타이드를 포함하는 백신 조성물, 사이클릭 펩타이드에 대한 항체 또는 이를 포함하는 항암 조성물
EP3712180A4 (en) 2017-11-16 2021-08-11 Orum Therapeutics Inc. RAS INHIBITOR ANTIBODIES ACTIVATED IN A CELL BY INTERNALIZATION IN CYTOSOL OF THE CELL, AND ITS USE
WO2019244086A1 (en) 2018-06-21 2019-12-26 Orum Therapeutics Inc. Cell/tissue-specific cell-penetrating antibodies

Also Published As

Publication number Publication date
CA3025757A1 (en) 2017-11-30
US11155641B2 (en) 2021-10-26
IL263242A (en) 2018-12-31
NZ749020A (en) 2020-11-27
AU2017271189B2 (en) 2020-02-20
JP2019520086A (ja) 2019-07-18
WO2017204606A1 (ko) 2017-11-30
US20190144566A1 (en) 2019-05-16
MX2018014554A (es) 2019-09-09

Similar Documents

Publication Publication Date Title
BR112018074275A2 (pt) anticorpo de penetração no citosol e método de produção do mesmo
BR112017001304A2 (pt) método para posicionamento, em citoplasma, de anticorpo contendo forma de imunoglobulina completa penetrando em anticorpo através da membrana celular e uso do mesmo
CL2016002004A1 (es) Anticuerpos anti-jagged1 y métodos de uso
CO2018006714A2 (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
MX2019003489A (es) Moleculas del receptor de envolvimiento quimerico.
CL2017000954A1 (es) Moléculas de unión a antígeno biespecificas activadoras de células t
BR112019011138A2 (pt) composições e métodos relacionados com sistemas celulares para penetração em tumores sólidos
MX2019009839A (es) Celulas eritroides funcionalizadas.
BR112017020893A2 (pt) método para o tratamento de câncer
BR112017025813A2 (pt) método, kit ou composição, micróbio comensal benéfico, método para tratar ou prevenir o câncer e formulação bacteriana
MX2022008085A (es) Moleculas peque?as contra cereblon para mejorar la funcion efectora de los linfocitos t.
CR20180525A (es) Producción de ácido ribonucleico libre de células
BR112016020065A2 (pt) sítios específicos para modificar anticorpos para fazer imunoconjugados
CR20150021A (es) Método para convertir insectos o gusanos en flujos de nutrientes y composiciones obtenidas de esta manera
BR112016020287A2 (pt) células resistentes a vírus e usos das mesmas
CL2011002083A1 (es) Preparado proteico a partir de semillas de colza, con contenido de proteinas menor a 90%, en que el preparado tiene funcionalidad ligadora de agua, ligadora de aceite y emulsionante; procedimiento de obtencion del preparado proteico; su uso; y procedimiento de utilizacion energetica de las cascaras.
BR112017004231A2 (pt) processo para produzir um precipitado estável enriquecido em ficobiliproteínas
BR112017005253A2 (pt) método para produzir biomassa que tem um alto teor de exopolissacarídeo.
BR112017023761A2 (pt) composições e métodos para a produção biológica de metionina
AR103077A1 (es) Método para la producción de un sistema de administración farmacéutica
BR112017012210A2 (pt) solução conservante de célula, uso da mesma e método de produção de solução conservante de célula
CL2019000054A1 (es) Procedimiento para la fabricación de briquetas que contienen un compuesto de calcio y magnesio y un compuesto a base de hierro, y briquetas así obtenidas.
BR112018070188A2 (pt) uso de caulim como opacificante
CO2017000558A2 (es) Variantes de proteínas de unión al factor h
EA201791059A1 (ru) Композиции и способы получения полипептидов с модифицированным профилем гликозилирования в клетках растений

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2673 DE 29-03-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.